Результаты поиска - Sandra Robrecht

  • Отображение 1 - 18 результаты of 18
Отмена результатов
  1. 1
    Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia

    Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia по Valentin Goede, Kirsten Fischer, Sandra Robrecht, Adam Giza, Martin J.S. Dyer, Michael J. Eckart, Lothar Müller, Lukáš Smolej, Nadine Kutsch, Anna-Maria Fink, Stephan Stilgenbauer, Michael Hallek

    Опубликовано 2025
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  2. 2
    Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)

    Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG) по Sonia Jaramillo, Andreas Agathangelidis, Christof Schneider, Jasmin Bahlo, Sandra Robrecht, Eugen Tausch, Johannes Bloehdorn, Manuela Hoechstetter, Kirsten Fischer, Barbara Eichhorst, Valentin Goede, Michael Hallek, Hartmut Döhner, Richard Rosenquist, Paolo Ghia, Κώστας Σταματόπουλος, Stephan Stilgenbauer

    Опубликовано 2019
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  3. 3
    High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia

    High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia по Othman Al‐Sawaf, Esther Lilienweiss, Jasmin Bahlo, Sandra Robrecht, Anna-Maria Fink, Michaela Patz, Maneesh Tandon, Yanwen Jiang, William Schary, Matthias Ritgen, Eugen Tausch, Stephan Stilgenbauer, Barbara Eichhorst, Kirsten Fischer, Michael Hallek, Karl‐Anton Kreuzer

    Опубликовано 2020
    Полный текст Полный текст
    Carta
    Добавить в Избранное
    Сохранить в:
  4. 4
    Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study

    Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study по Othman Al‐Sawaf, Can Zhang, Tong Lu, Michael Z. Liao, Anesh Panchal, Sandra Robrecht, Travers Ching, Maneesh Tandon, Anna‐Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Sebastian Böttcher, Karl‐Anton Kreuzer, Brenda Chyla, Dale Miles, Clemens‐Martin Wendtner, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer

    Опубликовано 2021
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  5. 5
    Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

    Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia по H. Huber, Simone Edenhofer, Julia von Tresckow, Sandra Robrecht, Can Zhang, Eugen Tausch, Christof Schneider, Johannes Bloehdorn, Moritz Fürstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna Lena Illert, Jan Dürig, Sebastian Böttcher, Carsten Utoft Niemann, Michael Kneba, Anna-Maria Fink, Kirsten Fischer, Hartmut Döhner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer

    Опубликовано 2022
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  6. 6
    Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

    Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax по Eugen Tausch, Christof Schneider, Sandra Robrecht, Can Zhang, Anna Dolnik, Johannes Bloehdorn, Jasmin Bahlo, Othman Al‐Sawaf, Matthias Ritgen, Anna-Maria Fink, Barbara Eichhorst, Karl‐Anton Kreuzer, Maneesh Tandon, Kathryn Humphrey, Yanwen Jiang, William Schary, Lars Bullinger, Daniel Mertens, M. Porro Lurà, Michael Kneba, Hartmut Döhner, Kirsten Fischer, Michael Hallek, Stephan Stilgenbauer

    Опубликовано 2020
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  7. 7
    S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY

    S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY по Othman Al‐Sawaf, Sandra Robrecht, Can Zhang, Stefano Olivieri, Yi Meng Chang, Anna‐Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl‐Anton Kreuzer, Liliya Sivcheva, Carsten Utoft Niemann, Anthony P. Schwarer, Javier Loscertales, Robert Weinkove, Dirk Strumberg, Allanah Kilfoyle, Eva Diana Runkel, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer

    Опубликовано 2023
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  8. 8
    COVID-19 among fit patients with CLL treated with venetoclax-based combinations

    COVID-19 among fit patients with CLL treated with venetoclax-based combinations по Moritz Fürstenau, Petra Langerbeins, Nisha De Silva, Anna Maria Fink, Sandra Robrecht, Julia von Tresckow, Florian Simon, Karin Hohloch, Jolanda Droogendijk, Marjolein van der Klift, Ellen van der Spek, Thomas Illmer, Björn Schöttker, Kirsten Fischer, Clemens‐Martin Wendtner, Eugen Tausch, Stephan Stilgenbauer, Carsten Utoft Niemann, Michael Gregor, Arnon P. Kater, Michael Hallek, Barbara Eichhorst

    Опубликовано 2020
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  9. 9
    The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia

    The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia по Petra Langerbeins, Can Zhang, Sandra Robrecht, Paula Cramer, Moritz Fürstenau, Othman Al‐Sawaf, Julia von Tresckow, Anna‐Maria Fink, Karl‐Anton Kreuzer, Ursula Vehling‐Kaiser, Eugen Tausch, Lothar Müller, Michael J. Eckart, Rudolf Schlag, W. Freier, Tobias Gaska, Christina Balser, Marcel Reiser, Martina Stauch, Clemens‐Martin Wendtner, Kirsten Fischer, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek

    Опубликовано 2021
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  10. 10
    Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

    Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia по Othman Al‐Sawaf, Can Zhang, Hyun Yong Jin, Sandra Robrecht, Yoonha Choi, Sandhya Balasubramanian, Alex Kotak, Yi Meng Chang, Anna Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl‐Anton Kreuzer, Brenda Chyla, Joseph N. Paulson, Christian P. Pallasch, Lukas P. Frenzel, Martin Peifer, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer

    Опубликовано 2023
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  11. 11
    Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial

    Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial по Othman Al‐Sawaf, Rudy Ligtvoet, Sandra Robrecht, Janina Stumpf, Anna‐Maria Fink, Eugen Tausch, Christof Schneider, Sebastian Böettcher, Martin Mikusko, Matthias Ritgen, Johannes Schetelig, Julia von Tresckow, Ursula Vehling‐Kaiser, Tobias Gaska, Clemens‐Martin Wendtner, Bjoern Chapuy, Kirsten Fischer, Karl‐Anton Kreuzer, Stephan Stilgenbauer, Philipp B. Staber, Carsten Utoft Niemann, Michael Hallek, Barbara Eichhorst

    Опубликовано 2023
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  12. 12
    Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription

    Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription по Jennifer Edelmann, Karlheinz Holzmann, Eugen Tausch, Emily A. Saunderson, Billy Michael Chelliah Jebaraj, Daniela Steinbrecher, Anna Dolnik, Tamara J. Blätte, Dan A. Landau, Jenny Saub, Sven Estenfelder, Stefan Ibach, Florence Cymbalista, Véronique Leblond, Alain Delmer, Jasmin Bahlo, Sandra Robrecht, Kirsten Fischer, Valentin Goede, Lars Bullinger, Catherine J. Wu, Daniel Mertens, Gabriella Ficz, John G. Gribben, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer

    Опубликовано 2019
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  13. 13
    Long Term Follow‐up Data and Health‐Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)

    Long Term Follow‐up Data and Health‐Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG) по Nadine Kutsch, Jasmin Bahlo, Sandra Robrecht, Jeremy Franklin, Can Zhang, Christian Maurer, Nisha De Silva, Elisabeth Lange, Rudolf Weide, Michael Kiehl, Martin Sökler, Rudolf Schlag, Ursula Vehling‐Kaiser, Georg Köchling, Christoph Plöger, Michael Gregor, Torben Plesner, Marco Herling, Kirsten Fischer, Hartmut Döhner, Michael Kneba, Clemens‐Martin Wendtner, Wolfram Klapper, Karl‐Anton Kreuzer, Sebastian Böttcher, Stephan Stilgenbauer, Anna Maria Fink, Michael Hallek, Barbara Eichhorst

    Опубликовано 2020
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  14. 14
    Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial

    Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial по Carmen D. Herling, Florence Cymbalista, Carolin Groß-Ophoff-Müller, Jasmin Bahlo, Sandra Robrecht, Petra Langerbeins, Anna‐Maria Fink, Othman Al‐Sawaf, Raymonde Busch, Raphaël Porcher, Bruno Cazin, Brigitte Dreyfus, Stefan Ibach, Stéphane Leprêtre, Kirsten Fischer, Florian Kaiser, Barbara Eichhorst, Clemens-Martin Wentner, Manuela Hoechstetter, Hartmut Döhner, Véronique Leblond, Michael Kneba, Rémi Letestu, Sebastian Böttcher, Stephan Stilgenbauer, Michael Hallek, Vincent Lévy

    Опубликовано 2020
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  15. 15
    Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the phase 3 CLL14 study

    Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the phase 3 CLL14 study по Othman Al‐Sawaf, Sandra Robrecht, Can Zhang, Stefano Olivieri, Yi Meng Chang, Anna-Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl‐Anton Kreuzer, Liliya Sivcheva, Carsten Utoft Niemann, Anthony P. Schwarer, Javier Loscertales, Robert Weinkove, Dirk Strumberg, Allanah Kilfoyle, Beenish S. Manzoor, Dureshahwar Jawaid, Nnadozie Emechebe, Jacob Devine, Michelle Boyer, Eva Diana Runkel, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer

    Опубликовано 2024
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  16. 16
    Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

    Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions по Kirsten Fischer, Othman Al‐Sawaf, Jasmin Bahlo, Anna-Maria Fink, Maneesh Tandon, Mark Dixon, Sandra Robrecht, Simon Warburton, Kathryn Humphrey, Olga Samoylova, A. M. Liberati, Javier Pinilla‐Ibarz, Stephen Opat, Liliya Sivcheva, Katell Le Dû, Laura Fogliatto, Carsten Utoft Niemann, Robert Weinkove, Sue Robinson, Thomas J. Kipps, Sebastian Böettcher, Eugen Tausch, Rod Humerickhouse, Barbara Eichhorst, Clemens‐Martin Wendtner, Anton W. Langerak, Karl-Anton Kreuzer, Matthias Ritgen, Valentin Goede, Stephan Stilgenbauer, Mehrdad Mobasher, Michael Hallek

    Опубликовано 2019
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  17. 17
    S149 FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PROGRESSION‐FREE SURVIVAL AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES

    S149 FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PROGRESSION‐FREE SURVIVAL AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDIT... по Kirsten Fischer, Othman Al‐Sawaf, Jasmin Bahlo, Anna‐Maria Fink, Maneesh Tandon, Mark Dixon, Sandra Robrecht, Simon Warburton, K. Humphrey, Olga Samoylova, Anna Marina Liberati, Javier Pinilla‐Ibarz, Stephen Opat, Liliya Sivcheva, Katell Le Dû, Laura Fogliatto, Carsten Utoft Niemann, Robert Weinkove, Sue Robinson, Thomas J. Kipps, Sebastian Böettcher, Eugen Tausch, William Schary, Barbara Eichhorst, C.‐M. Wendtner, Anton W. Langerak, K.‐A. Kreuzer, Valentin Goede, Stephan Stilgenbauer, Mehrdad Mobasher, Matthias Ritgen, Michael Hallek

    Опубликовано 2019
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  18. 18
    First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

    First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, rando... по Moritz Fürstenau, Arnon P. Kater, Sandra Robrecht, Julia von Tresckow, Can Zhang, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindström, Gunnar Juliusson, Ann Janssens, Mark‐David Levin, Caspar da Cunha‐Bang, Christof Schneider, Neta Goldschmidt, Elisabeth Vandenberghe, Davide Rossi, Rudolf Benz, Thomas Nösslinger, Daniel Heintel, Christian Bjørn Poulsen, Ilse Christiansen, Henrik Frederiksen, Lisbeth Enggaard, Eduardus F. M. Posthuma, Djamila E. Issa, Hein P. J. Visser, Mar Bellido, Nadine Kutsch, Jan Dürig, Alexander Stehle, Matthias Vöhringer, Sebastian Böttcher, Clemens Schulte, Florian Simon, Anna‐Maria Fink, Kirsten Fischer, Emily Eva Holmes, Karl‐Anton Kreuzer, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Stephan Stilgenbauer, Michael Hallek, Carsten Utoft Niemann, Barbara Eichhorst

    Опубликовано 2024
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:

Инструменты поиска: